Non-Small Cell Lung Cancer Clinical Trial 20213139
[LCID Study Number: 20213139]
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
The purpose of this study is to compare overall survival (OS) of sacituzumab govitecan-hziy (SG) versus docetaxel in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy and anti-programmed death protein 1 (PD-1)/ programmed death ligand 1 (PD-L1) immunotherapy received either in combination or sequentially.
Disease/Condition: Non-Small Cell Lung Cancer
Department: Hematology and Oncology
Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3421